Entia Biosciences, Inc.
ERGO
$0.00
$0.00-50.00%
OTC PK
| 12/31/2016 | 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | |
|---|---|---|---|---|---|
| Revenue | 265.50K | 287.90K | 314.00K | 323.70K | 346.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 265.50K | 287.90K | 314.00K | 323.70K | 346.80K |
| Cost of Revenue | 91.50K | 112.50K | 120.70K | 131.80K | 131.00K |
| Gross Profit | 173.90K | 175.30K | 193.40K | 192.00K | 215.90K |
| SG&A Expenses | 1.34M | 1.18M | 1.26M | 1.92M | 2.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.43M | 1.29M | 1.38M | 2.05M | 2.26M |
| Operating Income | -1.17M | -1.00M | -1.07M | -1.73M | -1.92M |
| Income Before Tax | -1.40M | -1.27M | -1.34M | -2.01M | -2.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.40 | -1.27 | -1.34 | -2.01 | -2.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.40M | -1.27M | -1.34M | -2.01M | -2.26M |
| EBIT | -1.17M | -1.00M | -1.07M | -1.73M | -1.92M |
| EBITDA | -1.15M | -981.40K | -1.04M | -1.70M | -1.88M |
| EPS Basic | -0.05 | -0.04 | -0.05 | -0.08 | -0.12 |
| Normalized Basic EPS | -0.03 | -0.02 | -0.03 | -0.05 | -0.07 |
| EPS Diluted | -0.05 | -0.04 | -0.05 | -0.08 | -0.12 |
| Normalized Diluted EPS | -0.03 | -0.02 | -0.03 | -0.05 | -0.07 |
| Average Basic Shares Outstanding | 112.55M | 113.51M | 113.69M | 108.87M | 91.03M |
| Average Diluted Shares Outstanding | 112.55M | 113.51M | 113.69M | 108.87M | 91.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |